Cargando…

Weighing the Odds: Novel β-Lactam/β-Lactamase Inhibitor Use in Hospital-Acquired and Ventilator-Associated Pseudomonas aeruginosa Pneumonia for Patients Who Are Morbidly Obese

BACKGROUND: Pseudomonas aeruginosa is a leading cause of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). Novel β-lactam/β-lactamase inhibitor (BL/BLI) combinations are often used for these infections; however, limited data exist to guide the dosing of BL/BLI in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kunz Coyne, Ashlan J, Orzol, Carolina, Veve, Michael P, Rybak, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500045/ https://www.ncbi.nlm.nih.gov/pubmed/37720698 http://dx.doi.org/10.1093/ofid/ofad454

Ejemplares similares

High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2023)

Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
por: Kunz Coyne, Ashlan J., et al.
Publicado: (2022)

1114. Effectiveness and Safety of Beta-lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection
por: Kunz Coyne, Ashlan J, et al.
Publicado: (2021)

Efficacy of Noncarbapenem β-Lactams Compared to Carbapenems for Extended-Spectrum β-Lactamase–Producing Enterobacterales Urinary Tract Infections
por: Anderson, Daniel T, et al.
Publicado: (2022)

Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis
por: Muhammed, Maged, et al.
Publicado: (2017)

Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa
por: Haines, Robbie R., et al.
Publicado: (2022)

In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors
por: Shields, Ryan K, et al.
Publicado: (2023)

Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections
por: Holger, Dana J., et al.
Publicado: (2022)

Prevalence and Predictors of Pseudomonas aeruginosa Among Hospitalized Patients With Diabetic Foot Infections
por: Veve, Michael P, et al.
Publicado: (2022)

Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
por: Lee, Su Young, et al.
Publicado: (2023)

PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability
por: Montaner, Maria, et al.
Publicado: (2022)

Molecular Mechanism of the β-Lactamase Mediated β-Lactam Antibiotic Resistance of Pseudomonas aeruginosa Isolated From a Chinese Teaching Hospital
por: Lin, Hailong, et al.
Publicado: (2022)

2125. Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations against Serine-Carbapenemase producing Carbapenem-Resistant Pseudomonas aeruginosa
por: Lee, Su Young, et al.
Publicado: (2023)

600. β-Lactam Resistance Mechanisms in Pseudomonas aeruginosa Isolates Analyzed Using Whole-Genome Sequencing (WGS) and Transcriptions Analysis and Their Impact in Resistance to New β-Lactam/β-Lactamase Inhibitors
por: Castanheira, Mariana, et al.
Publicado: (2019)

Extensively Drug-Resistant Pseudomonas aeruginosa ST309 Harboring Tandem Guiana Extended Spectrum β-Lactamase Enzymes: A Newly Emerging Threat in the United States
por: Khan, Ayesha, et al.
Publicado: (2019)

1600. Susceptibility of β-Lactam-Resistant Pseudomonas aeruginosa to Other β-Lactams: Is There Truly a Lack of Cross-Resistance?
por: Patel, Twisha S, et al.
Publicado: (2019)

β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects
por: Glen, Karl A., et al.
Publicado: (2021)

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
por: Luci, Giacomo, et al.
Publicado: (2021)

681. In vitro Activity of the β-Lactamase Inhibitor QPX7728 in Combination with Several β-Lactams Against Acinetobacter baumannii (AB) and Pseudomonas aeruginosa (PSA)
por: Lomovskaya, Olga, et al.
Publicado: (2019)

Epidemiology and high incidence of metallo-β-lactamase and AmpC-β-lactamases in nosocomial Pseudomonas aeruginosa
por: Muddassir, Maria, et al.
Publicado: (2021)

Characteristics of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa in Korea
por: Hong, Jun Sung, et al.
Publicado: (2015)

Epidemiology and Characteristics of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa
por: Hong, Duck Jin, et al.
Publicado: (2015)

Analysis of Metallo-β-lactamases, oprD Mutation, and Multidrug Resistance of β-lactam Antibiotic-Resistant Strains of Pseudomonas aeruginosa Isolated from Southern China
por: Li, Fei, et al.
Publicado: (2020)

Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020
por: Sader, Helio S., et al.
Publicado: (2021)

Effect of Obesity on Clinical Failure of Patients Treated With β-Lactams
por: Pinner, Nathan A, et al.
Publicado: (2021)

Trimeric Tobramycin/Nebramine Synergizes β-Lactam Antibiotics against Pseudomonas aeruginosa
por: Dhiman, Shiv, et al.
Publicado: (2023)

Endemic Carbapenem-resistant Pseudomonas aeruginosa with Acquired Metallo-β-lactamase Determinants in European Hospital
por: Lagatolla, Cristina, et al.
Publicado: (2004)

Impact of Peptidoglycan Recycling Blockade and Expression of Horizontally Acquired β-Lactamases on Pseudomonas aeruginosa Virulence
por: Barceló, Isabel M., et al.
Publicado: (2022)

Phenotypic Detection of Metallo-β-Lactamase in Imipenem-Resistant Pseudomonas aeruginosa
por: Khosravi, Yalda, et al.
Publicado: (2012)

Biofilm Formation and β-Lactamase Production in Burn Isolates of Pseudomonas aeruginosa
por: Heydari, Samira, et al.
Publicado: (2015)

β-lactamase-mediated resistance in MDR-Pseudomonas aeruginosa from Qatar
por: Sid Ahmed, Mazen A., et al.
Publicado: (2020)

BADAN-conjugated β-lactamases as biosensors for β-lactam antibiotic detection
por: Au, Ho-Wah, et al.
Publicado: (2020)

Cryptic β-Lactamase Evolution Is Driven by Low β-Lactam Concentrations
por: Fröhlich, Christopher, et al.
Publicado: (2021)

Co-regulation of β-lactam resistance, alginate production and quorum sensing in Pseudomonas aeruginosa
por: Balasubramanian, Deepak, et al.
Publicado: (2011)

1601. Evaluation of Synergy with β-Lactams Plus Aztreonam Against Pseudomonas aeruginosa (PSA)
por: O’Donnell, J Nicholas, et al.
Publicado: (2019)

Transcriptional and post-transcriptional regulation of PenA β-lactamase in acquired Burkholderia pseudomallei β-lactam resistance
por: Chirakul, Sunisa, et al.
Publicado: (2018)

Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity
por: Chaudhry, Saira B., et al.
Publicado: (2019)

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
por: Alosaimy, Sara, et al.
Publicado: (2021)

Penicillin-Binding Proteins, β-Lactamases, and β-Lactamase Inhibitors in β-Lactam-Producing Actinobacteria: Self-Resistance Mechanisms
por: Martin, Juan F., et al.
Publicado: (2022)

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales
por: Lomovskaya, Olga, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1uklpj317ir1bqta8kk0j4tdf1